Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia

A collection of iPSC lines derived from AML patients capture leukemia genomes and phenotypes and produce xenografts nearly identical to the matched primary PDXs. iPSCs from different AML clones uniquely empower the study of subclonal mutations.

[1]  R. Collins,et al.  Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. , 2022, Cancer cell.

[2]  Christopher A. Miller,et al.  Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. , 2022, Blood cancer discovery.

[3]  P. A. Futreal,et al.  A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia , 2022, Nature Medicine.

[4]  M. Pellegrini,et al.  Mapping human haematopoietic stem cells from haemogenic endothelium to birth , 2022, Nature.

[5]  M. Cazzola,et al.  Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs , 2022, Blood advances.

[6]  C. Leslie,et al.  Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. , 2021, Cell stem cell.

[7]  Helena L. Crowell,et al.  muscat detects subpopulation-specific state transitions from multi-sample multi-condition single-cell transcriptomics data , 2020, Nature Communications.

[8]  A. Abate,et al.  Single cell mutation analysis of clonal evolution in myeloid malignancies , 2020, Nature.

[9]  Michael G. Kharas,et al.  Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. , 2020, Cell reports.

[10]  Kamil Slowikowski,et al.  Fast, sensitive, and accurate integration of single cell data with Harmony , 2019, Nature Methods.

[11]  J. Abkowitz,et al.  Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. , 2019, Blood.

[12]  S. Ogawa.  Genetics of MDS. , 2019, Blood.

[13]  S. Heath,et al.  Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes , 2019, Cell reports.

[14]  M. Stadtfeld,et al.  Cellular trajectories and molecular mechanisms of iPSC reprogramming. , 2018, Current opinion in genetics & development.

[15]  J. Teruya-Feldstein,et al.  Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs , 2018, Stem cell reports.

[16]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[17]  A. Gentles,et al.  Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. , 2017, Cell stem cell.

[18]  Michael G. Kharas,et al.  Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. , 2017, Cell stem cell.

[19]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[20]  E. Papapetrou.  Patient-derived induced pluripotent stem cells in cancer research and precision oncology , 2016, Nature Medicine.

[21]  G. Daley,et al.  Progress towards generation of human haematopoietic stem cells , 2016, Nature Cell Biology.

[22]  Gustavo F. Bayón,et al.  Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency , 2016, Stem cell reports.

[23]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[24]  Fabian J Theis,et al.  Diffusion pseudotime robustly reconstructs lineage branching , 2016, Nature Methods.

[25]  Fabian J. Theis,et al.  destiny: diffusion maps for large-scale single-cell data in R , 2015, Bioinform..

[26]  J. Delrow,et al.  Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells , 2015, Nature Biotechnology.

[27]  Peter Reinhardt,et al.  Investigating human disease using stem cell models , 2014, Nature Reviews Genetics.

[28]  Christopher A. Miller,et al.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.

[29]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[30]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[31]  David A. Williams,et al.  Overcoming reprogramming resistance of Fanconi anemia cells. , 2012, Blood.

[32]  M. Sadelain,et al.  Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites , 2011, Nature Protocols.

[33]  Michel Sadelain,et al.  Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells , 2011, Nature Biotechnology.

[34]  C. Pereira,et al.  Senescence impairs successful reprogramming to pluripotent stem cells. , 2009, Genes & development.

[35]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[36]  Manuel Serrano,et al.  A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.

[37]  M. Blasco,et al.  The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.

[38]  J. Utikal,et al.  Immortalization eliminates a roadblock during cellular reprogramming into iPS cells , 2009, Nature.

[39]  A. Consiglio,et al.  Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells , 2009, Nature.

[40]  E. Estey,et al.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.

[41]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[42]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[43]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[44]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.